Pathogenic Effects of Glucosyltransferase from Clostridium Difficile Toxins

Overview

Journal Pathog Dis

Publisher Oxford University Press

Specialties Infectious Diseases
Microbiology

Date 2016 Apr 6

PMID 27044305

Citations 4

Authors

Yongrong Zhang

Hanping Feng

Affiliations

Soon will be listed here.

Abstract

The glucosyltransferase domain ofClostridium difficiletoxins modifies guanine nucleotide-binding proteins of Rho family. It is the major virulent domain of the holotoxins. Various pathogenic effects ofC. difficiletoxins in response to Rho glucosylation have been investigated including cytoskeleton damage, cell death and inflammation. The most recent studies have revealed some significant characteristics of the holotoxins that are independent of glucosylating activity. These findings arouse discussion about the role of glucosyltransferase activity in toxin pathogenesis and open up new insights for toxin mechanism study. In this review, we summarize the pathogenic effects of glucosyltransferase domain of the toxins in the past years.

Citing Articles

Advances in the mechanism of metformin with wide-ranging effects on regulation of the intestinal microbiota.

Wang Y, Jia X, Cong B Front Microbiol. 2024; 15:1396031.

PMID: 38855769 PMC: 11157079. DOI: 10.3389/fmicb.2024.1396031.

Exploring the Toxin-Mediated Mechanisms in Infection.

Pourliotopoulou E, Karampatakis T, Kachrimanidou M Microorganisms. 2024; 12(5).

PMID: 38792835 PMC: 11124097. DOI: 10.3390/microorganisms12051004.

The development of live biotherapeutics against infection towards reconstituting gut microbiota.

Zhang Y, Saint Fleur A, Feng H Gut Microbes. 2022; 14(1):2052698.

PMID: 35319337 PMC: 8959509. DOI: 10.1080/19490976.2022.2052698.

Phosphorylation and functionality of CdtR in Clostridium difficile.

Bilverstone T, Minton N, Kuehne S Anaerobe. 2019; 58:103-109.

PMID: 31323291 PMC: 6699598. DOI: 10.1016/j.anaerobe.2019.102074.

References

Genisyuerek S, Papatheodorou P, Guttenberg G, Schubert R, Benz R, Aktories K . Structural determinants for membrane insertion, pore formation and translocation of Clostridium difficile toxin B. Mol Microbiol. 2011; 79(6):1643-54. DOI: 10.1111/j.1365-2958.2011.07549.x. View

Koon H, Ho S, Hing T, Cheng M, Chen X, Ichikawa Y . Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum. Antimicrob Agents Chemother. 2014; 58(8):4642-50. PMC: 4135997. DOI: 10.1128/AAC.02783-14. View

Na X, Zhao D, Koon H, Kim H, Husmark J, Moyer M . Clostridium difficile toxin B activates the EGF receptor and the ERK/MAP kinase pathway in human colonocytes. Gastroenterology. 2005; 128(4):1002-11. DOI: 10.1053/j.gastro.2005.01.053. View

Giesemann T, Guttenberg G, Aktories K . Human alpha-defensins inhibit Clostridium difficile toxin B. Gastroenterology. 2008; 134(7):2049-58. DOI: 10.1053/j.gastro.2008.03.008. View

Just I, Wilm M, SELZER J, Rex G, von Eichel-Streiber C, Mann M . The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J Biol Chem. 1995; 270(23):13932-6. DOI: 10.1074/jbc.270.23.13932. View

Carter G, Chakravorty A, Nguyen T, Mileto S, Schreiber F, Li L . Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections. mBio. 2015; 6(3):e00551. PMC: 4453007. DOI: 10.1128/mBio.00551-15. View

DAuria K, Bloom M, Reyes Y, Gray M, Van Opstal E, Papin J . High temporal resolution of glucosyltransferase dependent and independent effects of Clostridium difficile toxins across multiple cell types. BMC Microbiol. 2015; 15:7. PMC: 4323251. DOI: 10.1186/s12866-015-0361-4. View

von Eichel-Streiber C, Sauerborn M, Kuramitsu H . Evidence for a modular structure of the homologous repetitive C-terminal carbohydrate-binding sites of Clostridium difficile toxins and Streptococcus mutans glucosyltransferases. J Bacteriol. 1992; 174(20):6707-10. PMC: 207659. DOI: 10.1128/jb.174.20.6707-6710.1992. View

Qadan M, Ramsey M, Daniel J, Spyres L, Safiejko-Mroczka B, Ortiz-Leduc W . Clostridium difficile toxin B activates dual caspase-dependent and caspase-independent apoptosis in intoxicated cells. Cell Microbiol. 2002; 4(7):425-34. DOI: 10.1046/j.1462-5822.2002.00201.x. View

10.

Zemljic M, Rupnik M, Scarpa M, Anderluh G, Palu G, Castagliuolo I . Repetitive domain of Clostridium difficile toxin B exhibits cytotoxic effects on human intestinal epithelial cells and decreases epithelial barrier function. Anaerobe. 2010; 16(5):527-32. DOI: 10.1016/j.anaerobe.2010.06.010. View

11.

Lica M, Schulz F, Schelle I, May M, Just I, Genth H . Difference in the biological effects of Clostridium difficile toxin B in proliferating and non-proliferating cells. Naunyn Schmiedebergs Arch Pharmacol. 2011; 383(3):275-83. DOI: 10.1007/s00210-010-0595-5. View

12.

Yu H, Chen K, Wu J, Yang Z, Shi L, Barlow L . Identification of toxemia in patients with Clostridium difficile infection. PLoS One. 2015; 10(4):e0124235. PMC: 4401762. DOI: 10.1371/journal.pone.0124235. View

13.

Rupnik M, Pabst S, Rupnik M, von Eichel-Streiber C, Urlaub H, Soling H . Characterization of the cleavage site and function of resulting cleavage fragments after limited proteolysis of Clostridium difficile toxin B (TcdB) by host cells. Microbiology (Reading). 2005; 151(Pt 1):199-208. DOI: 10.1099/mic.0.27474-0. View

14.

Yang Z, Zhang Y, Huang T, Feng H . Glucosyltransferase activity of Clostridium difficile Toxin B is essential for disease pathogenesis. Gut Microbes. 2015; 6(4):221-4. PMC: 4615278. DOI: 10.1080/19490976.2015.1062965. View

15.

He D, Hagen S, Pothoulakis C, Chen M, Medina N, Warny M . Clostridium difficile toxin A causes early damage to mitochondria in cultured cells. Gastroenterology. 2000; 119(1):139-50. DOI: 10.1053/gast.2000.8526. View

16.

Chaves-Olarte E, Weidmann M, Thelestam M . Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells. J Clin Invest. 1997; 100(7):1734-41. PMC: 508356. DOI: 10.1172/JCI119698. View

17.

Postma N, Kiers D, Pickkers P . The challenge of Clostridium difficile infection: Overview of clinical manifestations, diagnostic tools and therapeutic options. Int J Antimicrob Agents. 2015; 46 Suppl 1:S47-50. DOI: 10.1016/j.ijantimicag.2015.11.001. View

18.

Ho J, Greco A, Rupnik M, Ng K . Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A. Proc Natl Acad Sci U S A. 2005; 102(51):18373-8. PMC: 1317924. DOI: 10.1073/pnas.0506391102. View

19.

DAuria K, Kolling G, Donato G, Warren C, Gray M, Hewlett E . In vivo physiological and transcriptional profiling reveals host responses to Clostridium difficile toxin A and toxin B. Infect Immun. 2013; 81(10):3814-24. PMC: 3811747. DOI: 10.1128/IAI.00869-13. View

20.

Jochim N, Gerhard R, Just I, Pich A . Impact of clostridial glucosylating toxins on the proteome of colonic cells determined by isotope-coded protein labeling and LC-MALDI. Proteome Sci. 2011; 9:48. PMC: 3176154. DOI: 10.1186/1477-5956-9-48. View